irinotecan has been researched along with Adverse Drug Event in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (20.63) | 29.6817 |
| 2010's | 41 (65.08) | 24.3611 |
| 2020's | 9 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Bilić, I; Božina, N; Ganoci, L; Lešnjaković, L; Pleština, S; Šimičević, L; Trkulja, V | 1 |
| Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M | 1 |
| Bhan, AK; Donnell, SO; Kaliannan, K; Kang, C; Kang, JX; Li, XY; Murphy, K; Stanton, C; Wang, B | 1 |
| Kong, L; Rong, L; Wang, M | 1 |
| Hikino, K; Kamatani, Y; Koido, M; Kubo, M; Murakami, Y; Mushiroda, T; Ozeki, T; Terao, C | 1 |
| Artola, M; Bhatt, AP; Cloer, EW; Davies, GJ; Goldfarb, D; Jariwala, PB; Major, MB; Overkleeft, HS; Pellock, SJ; Redinbo, MR; Roberts, LR; Simpson, JB; Walton, WG | 1 |
| Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA | 1 |
| Deenen, MJ; Gelderblom, H; Guchelaar, HJ; Hulshof, EC | 1 |
| Aoki, Y; Chandler, RE; Lönnstedt, IM; Wakao, R | 1 |
| Gao, J; Li, J; Li, Y; Liu, D; Shen, L; Yang, R | 1 |
| Barnes, J; Cronin, A; Jasper, P; Mettetal, JT; Shankaran, H; Sharma, P; Tolsma, J | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Fokoue-Nkoutche, A; Hu, J; Luo, H; Singh, N; Yang, L; Zhang, P | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Fujita, KI; Ishida, H; Iwai, S; Kamei, D; Kubota, Y; Sasaki, Y; Taki-Takemoto, I; Tsuboya, A | 1 |
| Ge, K; Jia, C; Wang, Z; Wu, Q; Xu, X; Zheng, S | 1 |
| Filip, S; Nekvindová, J; Paulík, A | 1 |
| Fujii, H; Iihara, H; Kobayashi, R; Matsuhashi, N; Suzuki, A; Takahashi, T; Yoshida, K; Yoshimi, C | 1 |
| Addeo, P; Bachellier, P; Bahary, N; Bali, MA; Bekaii-Saab, T; Besselink, MG; Beumer, BR; Boone, BA; Buettner, S; Chau, I; Clarke, S; Dillhoff, M; El-Rayes, BF; Frakes, JM; Groot Koerkamp, B; Grose, D; Homs, MYV; Hosein, PJ; Jamieson, NB; Janssen, QP; Javed, AA; Katz, MHG; Khan, K; Kim, KP; Kim, SC; Kim, SS; Ko, AH; Lacy, J; Margonis, GA; McCarter, MD; McKay, CJ; Mellon, EA; Moorcraft, SY; Okada, KI; Paniccia, A; Parikh, PJ; Peters, NA; Rabl, H; Samra, J; Suker, M; Tinchon, C; van Eijck, CHJ; van Tienhoven, G; van Veldhuisen, E; Wang-Gillam, A; Weiss, MJ; Wilmink, JW; Yamaue, H | 1 |
| Páez, D | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Gao, J; Jia, R; Li, Y; Lu, M; Shen, L; Zhou, J | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Kosaki, K; Makita, K; Nomura, H; Okubo, K; Saito, K; Susumu, N; Tanigawara, Y; Tominaga, E; Zama, T | 1 |
| Cao, W; Cheng, C; Huo, BL; Wang, YH; Zhang, E | 1 |
| Abramson, V; Anders, C; Berg, J; Carey, LA; Carpenter, JT; Deal, AM; Karginova, O; Kelly Marcom, P; Lin, NU; Liu, MC; Melhem-Bertrandt, A; Melisko, M; Nanda, R; Parker, J; Perou, CM; Peterman, A; Prat, A; Puhalla, S; Smith, JK; Stearns, V; Storniolo, AM; Van Poznak, C; Winer, EP; Wolff, AC | 1 |
| Kaniwa, N | 1 |
| Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A | 1 |
| Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG | 1 |
| Wagner, LM | 1 |
| Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Bai, JP | 1 |
| Fujiwara, Y; Minami, H | 1 |
| Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M | 1 |
| Bruns, H; Büchler, MW; Hoffmann, K; Longerich, T; Mikalauskas, S; Mikalauskiene, L; Nickkholgh, A; Schemmer, P; Strupas, K | 1 |
| Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K | 1 |
| Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Baylatry, MT; Fernandez, C; Ghegediban, H; Joly, AC; Lacombe, P; Laurent, A; Lewis, A; Pelage, JP; Wassef, M | 1 |
| Chen, X; Guo, R; Jin, S; Shu, Y; Sun, J; Wang, T; Xu, B | 1 |
| Deepak, P; Ehrenpreis, ED | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
| Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
| Barni, S; Cazzaniga, M; Cremonesi, M; Ferretti, G; Ghilardi, M; Mandalà, M; Mary, C; Rezzani, C | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Agostara, B; Barone, C; Bordonaro, R; Borsellino, N; Capasso, E; Del Prete, S; Ferraù, F; Gebbia, V; Leonardi, V; Maiello, E; Stinco, S; Tralongo, P; Verderame, F | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Innocenti, F; Ratain, MJ; Vokes, EE | 1 |
| Asaka-Amano, Y; Kawashima, T; Kuriyama, T; Kurosu, K; Moriya, T; Nagao, K; Tada, Y; Takiguchi, Y | 1 |
| Hahm, JR; Hwang, IG; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Chang, HM; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Elinzano, H; Jin, T; Kang, TY; Peereboom, D | 1 |
13 review(s) available for irinotecan and Adverse Drug Event
| Article | Year |
|---|---|
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenomic Testing; Polymorphism, Single Nucleotide | 2020 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2019 |
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Topics: ATP-Binding Cassette Transporters; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Liver-Specific Organic Anion Transporter 1; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine | 2020 |
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2019 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Deoxycytidine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Genomics; Glucuronosyltransferase; HLA Antigens; Humans; International Cooperation; Irinotecan; Japan; Pharmacogenetics; Precision Medicine; Prodrugs; Product Surveillance, Postmarketing | 2015 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
Topics: Administration, Oral; Camptothecin; Clopidogrel; Drug Evaluation; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Membrane Transport Proteins; Models, Biological; Models, Statistical; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic; Ticlopidine | 2010 |
An overview of the recent progress in irinotecan pharmacogenetics.
Topics: Alleles; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Dinucleotide Repeats; Drug-Related Side Effects and Adverse Reactions; Gene Frequency; Glucuronosyltransferase; Haplotypes; Homozygote; Humans; Irinotecan; Models, Biological; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2010 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
Diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colitis; Colon; Colonoscopy; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enterocolitis, Pseudomembranous; Gastrointestinal Motility; Humans; Irinotecan; Muscle Contraction; Sodium-Potassium-Exchanging ATPase; Steatorrhea | 2011 |
17 trial(s) available for irinotecan and Adverse Drug Event
| Article | Year |
|---|---|
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Sex Characteristics; Survival Rate | 2020 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab | 2016 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Selection; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Polymorphism, Genetic; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden | 2010 |
Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2011 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2007 |
Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia | 2008 |
34 other study(ies) available for irinotecan and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Topics: Adult; Antimetabolites; Bayes Theorem; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genotype; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2022 |
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Topics: Aged; Analgesics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies; Treatment Outcome | 2021 |
Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome.
Topics: Animals; Antineoplastic Agents; Bacteria; Drug-Related Side Effects and Adverse Reactions; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Gastrointestinal Diseases; Gastrointestinal Microbiome; Irinotecan; Mice; RNA, Ribosomal, 16S | 2022 |
UGT1A1 Genetic Testing for Irinotecan Should be done before Starting the Treatment, Rather than after the Development of Serious Adverse Drug Reactions.
Topics: Drug-Related Side Effects and Adverse Reactions; Genetic Testing; Humans; Irinotecan | 2022 |
Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Biological Specimen Banks; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Male; Middle Aged; Polymorphism, Genetic | 2019 |
Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling.
Topics: Animals; Bacterial Proteins; Biomarkers; Computational Biology; Cyclohexanols; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Feces; Female; Gastrointestinal Microbiome; Glucuronidase; Glucuronides; Humans; Hydrolysis; Irinotecan; Kinetics; Male; Metabolome; Mice; Models, Molecular; Precision Medicine; Protein Binding; Protein Conformation | 2020 |
The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan.
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Humans; Irinotecan; Japan; Voriconazole | 2021 |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Topics: Adult; Aged; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged | 2017 |
Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Tract; Humans; Irinotecan; Models, Biological; Predictive Value of Tests; Species Specificity; Systems Biology; Translational Research, Biomedical | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Molecular Docking for Prediction and Interpretation of Adverse Drug Reactions.
Topics: Acneiform Eruptions; Algorithms; Binding Sites; Drug-Related Side Effects and Adverse Reactions; Fluticasone; Humans; Irinotecan; Libido; Machine Learning; Molecular Docking Simulation; Mometasone Furoate; Protein Binding; Protein Conformation; ROC Curve; Striae Distensae | 2018 |
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Agents; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylscopolammonium Bromide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Muscarinic Antagonists; Neoplasms; Parasympathetic Nervous System; Risk Factors; Syndrome | 2019 |
Genetics and adverse events with irinotecan treatment: what do we know?
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Genetics; Genotype; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 2019 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2013 |
Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Gene Frequency; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Polymorphism, Genetic; Retrospective Studies | 2013 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Safety | 2016 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Patient Care Management; Pharmacogenomic Testing; Pharmacogenomic Variants; Retrospective Studies; Topoisomerase I Inhibitors | 2017 |
Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Irinotecan; Maximum Tolerated Dose | 2010 |
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2010 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Female; Fluorouracil; Glycine; Immunohistochemistry; Irinotecan; Kupffer Cells; Leucovorin; Liver; Microcirculation; Neoadjuvant Therapy; Nitric Oxide Synthase Type II; Organoplatinum Compounds; Oxaliplatin; Phagocytosis; Rats; Rats, Sprague-Dawley; Transaminases | 2011 |
Pulmonary artery chemoembolization in a sheep model: Evaluation of performance and safety of irinotecan eluting beads (DEB-IRI).
Topics: Animals; Camptothecin; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Irinotecan; Microspheres; Pharmacokinetics; Pulmonary Artery; Sheep; Tissue Distribution; Topoisomerase I Inhibitors | 2011 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gilbert Disease; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Irinogenetics: what is the right star?
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug-Related Side Effects and Adverse Reactions; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2006 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |